Serious Adverse Event Report Form A

UoL Sponsored Clinical Trials of Investigational Medicinal Products

Guidance Document

All Serious Adverse Events **MUST** be reported within 24 hours of the research team being aware of the event. The initial report may be submitted without a PI signature, but must be followed up with a signed copy reporting expectedness and causality within 7 days.

Once a signed initial report is received a follow up or final report should be submitted within 28 days. If the patient is still an inpatient or there is an unavoidable delay in the provision of further information, inform the sponsor at the Research Governance Office.

Should there be a requirement for clarification or further information required, an email detailing the request will be sent. Response to the request is required as per the timelines dictated in the email.

| Sponsor Ref | Study identifier given by the Sponsor. This can be found on the Sponsor green light letter. This MUST be given to enable sponsor to identify the trial. |
| Study Title | Full or short version of the study title as per entered on the IRAS form |
| Study Number/Initials | Enter unique subject identifier and subjects initials. |
| Centre | Enter study centre name and code if applicable. |

**NO OTHER PATIENT IDENTIFIABLE DATA MUST BE ENTERED ON THIS FORM**

1. **Type of Report**

   - **Initial Report**
     The first time you are reporting this event, this may be a signed or unsigned report. At this time point either not all details are available, the form is unsigned, or the event is marked as ongoing.

   - **Follow Up Report**
     Follow up information to an initial report is being provided in this report. The event may still be marked as ongoing or resolved. If ongoing, further reports must be submitted until the resolution of the event.

   - **Final report**
When all follow up information is available for this Serious Adverse Event and outcome for the event has been completed.

**Initial and Final**
All information on the SAE and outcome of the event are complete on the first submission of the SAE report.

**Date of Report**
Date you are completing this report. (Initial /Follow up/Final).

**Serious Adverse Event**
Enter keywords that best summarise the event. e.g. admission for chest pain.

**Multiple Serious Adverse Events MUST be reported on individual forms.**

**Date of Onset**
Date of onset of the event reported. If a full date is not known either on the first or subsequent reports then UNK/ Month /Year should be completed.

**Date study Team Aware**
The date that the event was reported to/or the study team became aware of the event. The SAE must be submitted within 24 hours of this date.

2. **Seriousness Criteria**
Choose from the menu. If there is more than one criteria, choose the most significant one. Multiple Serious Adverse Events MUST be reported on individual forms.

3. **Narrative**
If the SAE is due to an admission to hospital, provide the admission and discharge dates. Provide an account of the event, similar to that of a discharge summary. The description must have sufficient details for evaluation by the individuals reviewing the SAE, who may not be experts in the disease area or investigational medicinal products. Abbreviations of clinical conditions should not be used. Summarise any relevant laboratory or diagnostic tests. Include details of discharge if appropriate.

4. **Causality and Expectedness**
This section must be completed by the Chief/Principal Investigator or other medically qualified investigator, as agreed by the Sponsor, and delegated this role on the Delegation of Authority and signature Log by the Principal Investigator.

All Investigational drugs should be entered and their causal relationship and expectedness, or not, MUST be reported.

If more than two drugs are under investigation an additional section can be added.
**Study Drug 1**  Enter details of IMP involved.

**Evaluation of Causal relationship to drug – Mark relevant box**

**Related** – if the causal relationship between the IMP and the SAE is at least a reasonable possibility i.e. the relationship cannot be ruled out

**Not Related** - If there is no causal relationship between the IMP and the SAE i.e. the event is caused by something other than the IMP e.g. underlying disease, a concomitant medication.

**Expectedness**

The assessment of expectedness MUST be based ONLY on the information contained in the APPROVED Reference Safety Information (RSI) i.e. Investigator Brochure and/or the Summary of Product Characteristics.

**Expected**- The event is an expected reaction based on the information contained in the Investigator Brochure and/or Summary of Product Characteristics.

**Unexpected** The event is unexpected based on the information contained in the Investigator Brochure and/or Summary of Product Characteristics.

**Study Drug 2** Enter second drug completing all details as above

**If the event is related and unexpected it is a Suspected Unexpected Serious Adverse Reaction (SUSAR) and requires expedited reporting. Inform the Sponsor immediately**

Telephone number 0116 258 4099 / 258 4867 / 258 8305

5. Is the study drug blinded or unblinded  
Detail if the study drug(s) the participants are receiving are known to the Investigator team or are blinded.

If a SUSAR has been reported blinded studies must be unblinded as per unblinding procedure.

6. Event related to protocol violation  
Answer Yes or No.  
If Yes - Further information should be supplied on a separate protocol deviation form.
7. Study Medication Information

Answer Yes or No. If Yes, further information on when study drug given should be provided in the table provided within the form.

8. Action taken with IMP

Please indicate action taken.

If participant not taking IMP at time of event mark as not applicable.

9. Patient Withdrawn

Answer Yes or No

10. Outcome

Resolved - The Serious Adverse event has resolved e.g. patient has been hospitalised, received treatment and the event has resolved. Provide details of the date of resolution of the SAE.

Resolved with Sequela – The Serious Adverse Event is resolved but there are still some residual problems as a result of the SAE e.g. the patient hospitalised for DVT and then discharged on warfarin. The patient no longer requires hospital treatment but the pre-existing symptoms persist.

Ongoing – The Event has not resolved at this time. This will require follow up until resolution of event.

Unknown at Present - Information is not available at the present time. Further information MUST be supplied until resolution of event.

Fatal - Where the event is fatal details of the date of death and the cause of death MUST be obtained.

Cause of death obtained - detail where the information was obtained to support cause of death. Supporting documents to be supplied with SAE.

Note all supporting documentation must have all patient identifiable data removed. The documents MUST only be identified with the addition of the patient study ID and initials.

Reporting Person

Supply full details of person reporting the event as indicated. Please ensure contact phone number and email address are complete.

Principal Investigator/Delegated Medically qualified individual

Supply full details. Please Note* the person signing this form must be either the Principal Investigator or a medically qualified individual as agreed by Sponsor to undertake this role. The person must be named and delegated the duty on the delegation of authority log.

Reporting and completion of SAEs involving investigational medicinal products must be undertaken in accordance with SOP S-1009 – Processing and Reporting of Serious Adverse Events, Serious Adverse Reactions and Suspected Unexpected Serious Adverse Reactions for all Research Sponsored by the University of Leicester.
Please return the completed form and any anonymised copies of supporting documents to the Research Governance Office by email to rgosponsor@leicester.ac.uk

If you have queries regarding your SAE submission, please contact the Research Governance Office. Contact details can be found on the UoL Research Governance Website.

http://www2.le.ac.uk/colleges/medbiopsych/research/researchgovernance/ethics